Obinutuzumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Obinutuzumab
- Obinutuzumab: From Chronic Lymphocytic Leukemia to Pregerminal Center CLL/SLL (Molecular Subtype)
Obinutuzumab: From Chronic Lymphocytic Leukemia to Pregerminal Center CLL/SLL (Molecular Subtype)
One-Sentence Summary
Obinutuzumab is a glycoengineered, type II anti-CD20 monoclonal antibody already established in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. The TxGNN model’s top-ranked prediction, pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma, is a molecular subgroup of CLL/SLL rather than an independent disease entity, and currently has 0 clinical trials and 0 publications specifically indexed against it — the model score of 99.21% likely reflects the drug’s already-proven efficacy in CLL as a whole, not a genuinely new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed via EMA licensing data (0 authorizations on record); contextual evidence in this pack references obinutuzumab’s established use in chronic lymphocytic leukemia (CLL11 trial) |
| Predicted New Indication | Pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma |
| TxGNN Prediction Score | 99.21% |
| Evidence Level | L1 (pipeline-assigned; see caveat below — driven by existing CLL approval, not by direct trials/literature for this specific molecular subtype) |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed DrugBank-sourced mechanism-of-action data is not available in this evidence pack. Based on information embedded in the repurposing rationale, obinutuzumab is a third-generation, glycoengineered, type II anti-CD20 monoclonal antibody. Its mechanism combines enhanced direct B-cell killing with increased antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) compared with first-generation anti-CD20 agents such as rituximab. It has been approved based on pivotal trials including CLL11 (chronic lymphocytic leukemia) and GALLIUM (follicular lymphoma).
“Pregerminal center CLL/SLL” and “CLL/SLL with IGHV somatic hypermutation” are not distinct diseases — they are biological subgroups of CLL/SLL defined by immunoglobulin heavy-chain variable-region (IGHV) mutation status and cell-of-origin. Because obinutuzumab’s target, CD20, is expressed on malignant B cells regardless of IGHV mutation status, there is no mechanistic reason to expect differential efficacy between subgroups. This explains the very high TxGNN score: the model is essentially re-discovering an already-approved indication expressed at finer ontological granularity, rather than proposing a genuinely novel therapeutic hypothesis.
This also explains the absence of dedicated trials or literature for this exact label — evidence-collection pipelines typically filter out “known indications” (CLL as a whole) when searching for new uses, and the finer-grained subtype label falls into a gap between “already known” and “genuinely novel.” As a result, this specific candidate should be treated as a taxonomy artifact rather than an actionable repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EMA marketing authorizations are on record for obinutuzumab in this evidence pack (0 licenses; market status: Not Marketed). This may reflect a genuine absence of EU marketing authorization, or a gap in the data source used to compile this pack — it should be confirmed against the EMA product database before any regulatory conclusion is drawn.
Cytotoxicity (Antineoplastic Drug)
Obinutuzumab is an antineoplastic biologic (anti-CD20 monoclonal antibody used in CLL/lymphoma), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy / immunotherapy — glycoengineered, type II anti-CD20 monoclonal antibody (not conventional cytotoxic chemotherapy) |
| Myelosuppression Risk | Moderate–High — neutropenia, including prolonged/late-onset neutropenia, is a well-documented effect of the anti-CD20 antibody class in CLL/lymphoma trials; please refer to the SmPC for graded incidence data |
| Emetogenicity Classification | Low — minimal direct emetogenic potential; the dominant acute toxicity is infusion-related reaction rather than nausea/vomiting |
| Monitoring Items | CBC with differential (neutropenia, thrombocytopenia), infusion-related reaction monitoring during and after infusion, hepatitis B screening (reactivation risk with B-cell depleting antibodies), serum immunoglobulin levels |
| Handling Protection | Monoclonal antibodies are generally not subject to cytotoxic hazardous-drug handling protocols, but standard biologic infusion precautions, premedication, and infusion-reaction management procedures are required |
Please refer to the SmPC warnings and precautions for full toxicity grading.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked candidate, “pregerminal center CLL/SLL,” has zero supporting clinical trials or literature (decision stage S0) and, per the underlying rationale, most likely represents a known-indication subgroup rather than a genuinely new therapeutic use. Pursuing this as a standalone repurposing candidate is not currently justified.
To proceed, the following is needed:
- Resolve blocking data gap DG001 (TFDA/EMA label warnings and contraindications) before any safety-stage review can begin
- Resolve high-priority data gap DG002 (formal mechanism-of-action data from DrugBank)
- Clarify whether TxGNN’s disease ontology should collapse CLL/SLL molecular subtypes into the parent “CLL/SLL” node to avoid inflating apparent “new indication” counts with known-indication artifacts
- Confirm actual EU/EMA marketing authorization status, since 0 licenses is currently unverified against the primary EMA source
Note for portfolio prioritization: among this drug’s other predicted indications, mantle cell lymphoma (rank 4, evidence level L2, decision stage S2, “Proceed with Guardrails”) is a substantially stronger candidate — it is not an approved indication, yet is supported by dozens of trials (including head-to-head studies) and recent high-quality literature (e.g., PMID 38669626, Blood 2024). It may warrant its own dedicated evaluation report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.